GlassScriptPhysician profile
Michael Thomas Cerniglia
NPI 1386106284
$3,327.10
in general payments reported to CMS, 2019-2025
32 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $895 · 2024: $942 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.18 |
| Education | $182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $484.99 | 2023-2025 | Venclexta |
| Genzyme Corporation | $271.83 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $199.93 | 2024-2025 | Tazverik, Onivyde, Somatuline Depot |
| Novartis Pharmaceuticals Corporation | $194.08 | 2025 | |
| Janssen Biotech, INC. | $168.71 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Alexion Pharmaceuticals, INC. | $160.94 | 2023-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $157.23 | 2023-2025 | Keytruda, Prevymis, Dificid |
| Karyopharm Therapeutics INC. | $156.26 | 2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $144.77 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Daiichi Sankyo INC. | $119.74 | 2023-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $116.67 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Celgene Corporation | $116.09 | 2023-2025 | Reblozyl |
| Boston Scientific Corporation | $105.94 | 2022 | |
| Pfizer INC. | $100.44 | 2024-2025 | |
| Abiomed | $91.89 | 2023 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $85.31 | 2023-2024 | Bavencio |
| Puma Biotechnology, INC. | $72.89 | 2024 | |
| Adc Therapeutics America, INC. | $70.66 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $69.85 | 2025 | |
| Jazz Pharmaceuticals INC. | $63.01 | 2023 | |
| Genentech USA, INC. | $52.55 | 2024-2025 | Tecentriq, Phesgo, Tecentriq Hybreza |
| Amgen INC. | $44.48 | 2023 | Blincyto, Kyprolis |
| Stemline Therapeutics INC. | $40.21 | 2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $34.86 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $33.84 | 2024-2025 | Lynparza, Enhertu |
| Exelixis INC. | $31.46 | 2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $28.21 | 2025 | Pyrukynd |
| Blueprint Medicines Corporation | $27.85 | 2024 | Ayvakit |
| Sumitomo Pharma America, INC. | $22.41 | 2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $22.26 | 2025 | Qinlock, Tgct |
| Coherus Oncology, INC. | $21.90 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.84 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cerniglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.